Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in approximately 2-7% of NSCLC patients and have been established as a key driver mutation in lung cancer (5, 6), particularly prevalent in younger patients and those with no smoking history (7). Here, ALK is linked to lung cancer.